Glucagon-like peptide-1 receptor is involved in learning

Nature Medicine

9, 1173-1179

DOI: 10.1038/nm919

Citation Report

#	Article	IF	Citations
1	Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. Journal of Neurochemistry, 2003, 87, 1137-1144.	2.1	95
2	Learning from the gut. Nature Medicine, 2003, 9, 1113-1115.	15.2	27
3	Glucagon-Like Peptide-1 and the Islet Î²-Cell: Augmentation of Cell Proliferation and Inhibition of Apoptosis. Endocrinology, 2003, 144, 5145-5148.	1.4	258
4	Genetic Dissection of Learning and Memory in Mice. Neural Plasticity, 2004, 11, 217-240.	1.0	10
5	On the Physiology of GIP and GLP-1. Hormone and Metabolic Research, 2004, 36, 747-754.	0.7	168
6	Physiology of GLP-1 - Lessons from Glucoincretin Receptor Knockout Mice. Hormone and Metabolic Research, 2004, 36, 766-770.	0.7	14
8	Minireview: Glucagon-Like Peptides Regulate Cell Proliferation and Apoptosis in the Pancreas, Gut, and Central Nervous System. Endocrinology, 2004, 145, 2653-2659.	1.4	486
9	INGAP peptide improves nerve function and enhances regeneration in streptozotocinâ€induced diabetic C57BL/6 mice. FASEB Journal, 2004, 18, 1767-1769.	0.2	39
10	The Metabolic Syndrome and Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2004, 59, M139-M142.	1.7	70
11	Brain Uptake of the Glucagon-Like Peptide-1 Antagonist Exendin(9-39) after Intranasal Administration. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 469-475.	1.3	132
12	Extrahypothalamic Expression of the Glucagon-Like Peptide-2 Receptor Is Coupled to Reduction of Glutamate-Induced Cell Death in Cultured Hippocampal Cells. Endocrinology, 2004, 145, 3495-3506.	1.4	69
13	Glucagon-Like Peptide-1: Regulation of Insulin Secretion and Therapeutic Potential. Basic and Clinical Pharmacology and Toxicology, 2004, 95, 252-262.	1.2	87
14	Mutant G-protein-coupled receptors as a cause of human diseases. , 2004, 104, 173-206.		281
15	Potent and selective proline derived dipeptidyl peptidase IV inhibitors. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5151-5155.	1.0	58
16	Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase IV (DPP IV) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5579-5583.	1.0	30
17	Antiaging methods and medicines for the memory. Clinics in Geriatric Medicine, 2004, 20, 317-328.	1.0	3
18	Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology, 2004, 127, 546-558.	0.6	320
19	Glucagon-like peptide-1 and glucagon-like peptide-2. Best Practice and Research in Clinical Endocrinology and Metabolism, 2004, 18, 531-554.	2.2	59

#	Article	IF	Citations
20	Glucagon-like Peptide-1:Â The Basis of a New Class of Treatment for Type 2 Diabetes. Journal of Medicinal Chemistry, 2004, 47, 4128-4134.	2.9	162
21	Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Current Opinion in Pharmacology, 2004, 4, 589-596.	1.7	108
22	Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential. Physiology, 2005, 20, 357-365.	1.6	72
23	Glucagon-like peptide-1: physiology and therapeutic potential. Current Opinion in Endocrinology, Diabetes and Obesity, 2005, 12, 56-62.	0.6	26
24	The incretins: a link between nutrients and well-being. British Journal of Nutrition, 2005, 93, S147-S156.	1.2	67
25	Discovery of potent and selective orally bioavailable Î²-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3048-3052.	1.0	49
26	Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes/Metabolism Research and Reviews, 2005, 21, 91-117.	1.7	250
27	Glucagon- and Secretin-Related Peptides Differentially Alter Ocular Growth and the Development of Form-Deprivation Myopia in Chicks. , 2005, 46, 3932.		48
28	Mediation of cognitive function by high fat diet following stress and inflammation. Nutritional Neuroscience, 2005, 8, 309-315.	1.5	22
29	The brainâ€“adipose axis: A review of involvement of molecules. Nutritional Neuroscience, 2005, 8, 7-20.	1.5	31
30	Enhancing Central Nervous System Endogenous GLP-1 Receptor Pathways for Intervention in Alzheimers Disease. Current Alzheimer Research, 2005, 2, 377-385.	0.7	113
31	Nutritional Status, Cognition, and Survival. Journal of Biological Chemistry, 2005, 280, 42142-42148.	1.6	103
32	Pancreatic Î²-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs. Journal of Molecular Endocrinology, 2005, 34, 377-390.	1.1	39
33	The pathogenesis of obesity: Stress and the brain-gut axis. Surgery for Obesity and Related Diseases, 2005, 1, 25-34.	1.0	8
34	The GLPâ€1 system as a therapeutic target. Annals of Medicine, 2005, 37, 314-322.	1.5	19
35	AAV-mediated hippocampal expression of short and long Homer 1 proteins differentially affect cognition and seizure activity in adult rats. Molecular and Cellular Neurosciences, 2005, 28, 347-360.	1.0	179
36	Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regulatory Peptides, 2005, 128, 97-107.	1.9	90
37	Antisecretory factor modulates GABAergic transmission in the rat hippocampus. Regulatory Peptides, 2005, 129, 109-118.	1.9	16

#	Article	IF	Citations
38	Glucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2005, 4, 361-370.	1.8	63
39	Development of Beta-Amyloid-induced Neurodegeneration in Alzheimer's Disease and Novel Neuroprotective Strategies. Reviews in the Neurosciences, 2005, 16, 181-212.	1.4	74
40	Gastrointestinal Peptide Hormones Regulating Energy and Glucose Homeostasis. , 2006, , 161-181.		1
41	The CNS as a target for peptides and peptide-based drugs. Expert Opinion on Drug Delivery, 2006, 3, 707-712.	2.4	36
42	Exendin-4 Uses Irs2 Signaling to Mediate Pancreatic Î² Cell Growth and Function. Journal of Biological Chemistry, 2006, 281, 1159-1168.	1.6	189
43	The biology of incretin hormones. Cell Metabolism, 2006, 3, 153-165.	7.2	1,824
44	GLP-1 and type 2 diabetes: physiology and new clinical advances. Current Opinion in Pharmacology, 2006, 6, 598-605.	1.7	46
45	A novel role of circadian transcription factor DBP in hippocampal plasticity. Molecular and Cellular Neurosciences, 2006, 31, 303-314.	1.0	32
46	Neurotrophic property of geniposide for inducing the neuronal differentiation of PC12 cells. International Journal of Developmental Neuroscience, 2006, 24, 419-424.	0.7	80
47	Design and Optimization of Expression Cassettes Including Promoter Choice and Regulatory Elements. , 2006, , 3-16.		2
48	Revenge of the â€œSitâ€: How lifestyle impacts neuronal and cognitive health through molecular systems that interface energy metabolism with neuronal plasticity. Journal of Neuroscience Research, 2006, 84, 699-715.	1.3	258
49	Glucagon and Glucagon-Like Peptide Receptors as Drug Targets. Current Pharmaceutical Design, 2006, 12, 1731-1750.	0.9	82
50	Genetic Manipulation of Learning and Memory. , 2006, , 167-179.		0
51	Effects of Sex and Insulin/Insulin-Like Growth Factor-1 Signaling on Performance in an Associative Learning Paradigm in Caenorhabditis elegans. Genetics, 2006, 174, 309-316.	1.2	38
52	Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1. Diabetes Care, 2006, 29, 435-449.	4.3	103
53	Quantitative trait loci for carbohydrate and total energy intake on mouse chromosome 17: congenic strain confirmation and candidate gene analyses (Glo1, Glp1r). American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 292, R207-R216.	0.9	29
54	Azetidine-Based Inhibitors of Dipeptidyl Peptidase IV (DPP IV). Current Topics in Medicinal Chemistry, 2007, 7, 597-608.	1.0	25
55	New Horizons in Diabetes Therapy. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2007, 7, 49-55.	0.5	3

#	Article	IF	Citations
56	GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2007, 1, 193-201.	0.7	0
57	Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Experimental Neurology, 2007, 203, 293-301.	2.0	166
58	Exploiting the pleiotropic actions of GLP-1 for the management of type 2 diabetes mellitus and its complications. Diabetes Research and Clinical Practice, 2007, 78, S59-S67.	1.1	8
59	The Physiology of Glucagon-like Peptide 1. Physiological Reviews, 2007, 87, 1409-1439.	13.1	2,504
60	Neuronal Apoptosis in Neurodegeneration. Antioxidants and Redox Signaling, 2007, 9, 1059-1096.	2.5	196
61	Small-molecule agonists for the glucagon-like peptide 1 receptor. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 937-942.	3.3	204
62	Biology of Incretins: GLP-1 and GIP. Gastroenterology, 2007, 132, 2131-2157.	0.6	2,918
63	Hyperglycemia in Acute Ischemic Stroke: A Vascular Perspective. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 435-451.	2.4	206
64	Hippocampal gene expression profiling reveals the possible involvement ofHomer1andGABABreceptors in scopolamine-induced amnesia. Journal of Neurochemistry, 2007, 102, 1978-1989.	2.1	39
65	Role of cysteine 341 and arginine 348 of GLP-1 receptor in G-protein coupling. Molecular Biology Reports, 2007, 34, 53-60.	1.0	5
66	Strategies for Intranasal Delivery of Therapeutics for the Prevention and Treatment of NeuroAIDS. Journal of NeuroImmune Pharmacology, 2007, 2, 81-86.	2.1	102
67	Glucagon-like Peptide-1 (GLP-1) Diminishes Neuronal Degeneration and Death Caused by NGF Deprivation by Suppressing Bim Induction. Neurochemical Research, 2008, 33, 1845-1851.	1.6	53
68	Peptide hormone exendinâ€4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease. Journal of Neuroscience Research, 2008, 86, 326-338.	1.3	282
69	Delivery of peptides to the brain: Emphasis on therapeutic development. Biopolymers, 2008, 90, 589-594.	1.2	58
70	Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2409-2413.	1.0	95
71	Brain foods: the effects of nutrients on brain function. Nature Reviews Neuroscience, 2008, 9, 568-578.	4.9	931
72	Molecular network of obesity: what does it promise for pharmacotherapy?. Obesity Reviews, 2008, 9, 236-245.	3.1	7
73	GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. European Journal of Pharmacology, 2008, 587, 112-117.	1.7	131

#	Article	IF	Citations
75	Role of Central Nervous System Glucagon-Like Peptide-1 Receptors in Enteric Glucose Sensing. Diabetes, 2008, 57, 2603-2612.	0.3	116
76	New Approaches to Treating Type 2 Diabetes Mellitus in the Elderly. Drugs and Aging, 2008, 25, 913-925.	1.3	61
77	Exendin-4 and exercise promotes Î²-cell function and mass through IRS2 induction in islets of diabetic rats. Life Sciences, 2008, 82, 503-511.	2.0	38
78	Delivery of interferon-Î² to the monkey nervous system following intranasal administration. Neuroscience, 2008, 152, 785-797.	1.1	210
79	Crucial role of insulin receptor substrateâ€2 in compensatory Î²â€cell hyperplasia in response to high fat dietâ€“induced insulin resistance. Diabetes, Obesity and Metabolism, 2008, 10, 147-156.	2.2	37
80	GLP-1 et systÃ¨me nerveuxÂ: un mÃ©canisme de son action antidiabÃ©tique. Medecine Des Maladies Metaboliques, 2008, 2, 502-508.	0.1	0
81	Insulin, Insulin-Like Growth Factors??and Incretins. CNS Drugs, 2008, 22, 443-453.	2.7	17
82	Delivery of Galanin-Like Peptide to the Brain: Targeting with Intranasal Delivery and Cyclodextrins. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 513-519.	1.3	94
83	Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failureâ€“Prone Rat. Circulation: Heart Failure, 2008, 1, 153-160.	1.6	156
84	The entero-insular axis: implications for human metabolism. Clinical Chemistry and Laboratory Medicine, 2008, 46, 43-56.	1.4	42
85	Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans. Diabetes, 2008, 57, 325-331.	0.3	39
86	Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptorâ€“Dependent and â€“Independent Pathways. Circulation, 2008, 117, 2340-2350.	1.6	885
87	The GLP-1 Concept in the Treatment of Type 2 Diabetesâ€”Still Standing at the Gate of Dawn?. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 375-377.	1.8	7
88	Recent Patents Review on Intranasal Administration for CNS Drug Delivery. Recent Patents on Drug Delivery and Formulation, 2008, 2, 25-40.	2.1	94
89	Commonality between Diabetes and Alzheimer's Disease and a New Strategy for the Therapy. Clinical Medicine Pathology, 2008, 1, CPath.S667.	0.0	11
90	Incretin-Based Therapy of Type 2 Diabetes Mellitus. Current Protein and Peptide Science, 2009, 10, 46-55.	0.7	40
91	Improved Learning and Memory in Aged Mice Deficient in Amyloid Î²-Degrading Neutral Endopeptidase. PLoS ONE, 2009, 4, e4590.	1.1	30
92	GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1285-1290.	3.3	483

#	Article	IF	Citations
93	Incretin-Based Therapies. Diabetes Care, 2009, 32, S223-S231.	4.3	143
94	Functional Characterization of N-Terminally GFP-Tagged GLP-1 Receptor. Journal of Biomedicine and Biotechnology, 2009, 2009, 1-10.	3.0	6
95	Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. Journal of Endocrinology, 2009, 202, 431-439.	1.2	223
96	Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact. Brain, 2009, 132, 2219-2230.	3.7	36
97	GLP - 1 Analogs: Newer Molecules, Newer Uses. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2009, 3, 129-134.	0.7	2
98	Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington's Disease. Diabetes, 2009, 58, 318-328.	0.3	160
99	Efficient Gene Delivery and Selective Transduction of Glial Cells in the Mammalian Brain by AAV Serotypes Isolated From Nonhuman Primates. Molecular Therapy, 2009, 17, 1692-1702.	3.7	150
100	Portal Vein Glucose Sensors Do Not Play a Major Role in Modulating Physiological Responses to Insulin-Induced Hypoglycemia in Humans. Diabetes, 2009, 58, 194-202.	0.3	9
101	Characteristics of compounds that cross the blood-brain barrier. BMC Neurology, 2009, 9, S3.	0.8	520
102	Effect of Dipeptidyl Peptidase-IV (DPP-IV) Inhibitor (Vildagliptin) on Peripheral Nerves in Streptozotocin-induced Diabetic Rats. Archives of Medical Research, 2009, 40, 536-544.	1.5	76
103	Protection of exendin-4 analogue in early experimental diabetic retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 699-706.	1.0	54
104	Insulin-Secreting Cells from Human Eyelid-Derived Stem Cells Alleviate Type I Diabetes in Immunocompetent Mice. Stem Cells, 2009, 27, 1999-2008.	1.4	65
105	Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta Pharmacologica Sinica, 2009, 30, 159-165.	2.8	134
106	Polyâ€GLPâ€1, a novel longâ€lasting glucagonâ€like peptideâ€1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic betaâ€cell proliferation. Diabetes, Obesity and Metabolism, 2009, 11, 953-965.	2.2	16
107	Harnessing the weightâ€regulating properties of glucagonâ€like peptideâ€1 in the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism, 2009, 11, 4-10.	2.2	4
108	Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4097-4101.	1.0	37
109	GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice. Diabetes, 2009, 58, 975-983.	0.3	491
110	Ciliary neurotrophic factor recruitment of glucagonâ€like peptideâ€1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons. FASEB Journal, 2009, 23, 4256-4265.	0.2	92

#	Article	IF	Citations
111	Incretin Therapies: Effects Beyond Glycemic Control. European Journal of Internal Medicine, 2009, 20, S319-S328.	1.0	17
112	Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behavioural Brain Research, 2009, 205, 265-271.	1.2	229
113	Embryonic nervous system genes predominate in searches for dinucleotide simple sequence repeats flanked by conserved sequences. Gene, 2009, 429, 74-79.	1.0	26
114	The incretin system and its role in type 2 diabetes mellitus. Molecular and Cellular Endocrinology, 2009, 297, 127-136.	1.6	447
115	Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury. Neuroscience Letters, 2009, 463, 176-181.	1.0	94
116	The influences of juvenile diabetes on memory and hippocampal plasticity in rats: Improving effects of glucagon-like peptide-1. Neuroscience Research, 2009, 64, 67-74.	1.0	49
117	Incretin Therapies: Effects Beyond Glycemic Control. American Journal of Medicine, 2009, 122, S25-S36.	0.6	30
118	Delivery of testosterone to the brain by intranasal administration: Comparison to intravenous testosterone. Journal of Drug Targeting, 2009, 17, 91-97.	2.1	56
119	Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. NeuroReport, 2009, 20, 1161-1166.	0.6	213
120	Geniposide Induces the Expression of Heme Oxygenase-1 via PI3K/Nrf2-Signaling to Enhance the Antioxidant Capacity in Primary Hippocampal Neurons. Biological and Pharmaceutical Bulletin, 2010, 33, 1841-1846.	0.6	57
121	Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow. American Journal of Physiology - Endocrinology and Metabolism, 2010, 298, E634-E643.	1.8	102
122	Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model. Cellular and Molecular Life Sciences, 2010, 67, 3711-3723.	2.4	39
123	Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?. Current Diabetes Reports, 2010, 10, 124-132.	1.7	42
124	Intranasal Delivery of Human Î²-Amyloid Peptide in Rats: Effective Brain Targeting. Cellular and Molecular Neurobiology, 2010, 30, 405-413.	1.7	28
125	Constructing glucagon like peptide-1 receptor fused with derivatives of GFP for visualizing proteinâ€“protein interaction in living cells. Molecular Biology Reports, 2010, 37, 2749-2755.	1.0	5
126	Effects of centrally-injected glucagon-like peptide-1 on pilocarpine-induced seizures, anxiety and locomotor and exploratory activity in rat. Neuropeptides, 2010, 44, 285-291.	0.9	26
127	Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regulatory Peptides, 2010, 164, 58-64.	1.9	141
128	Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease. European Journal of Pharmacology, 2010, 630, 158-162.	1.7	163

#	Article	IF	Citations
129	Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration. European Journal of Pharmacology, 2010, 641, 128-134.	1.7	42
130	Glucagonâ€like peptide 1 receptor stimulation as a means of neuroprotection. British Journal of Pharmacology, 2010, 159, 495-501.	2.7	107
131	Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. International Journal of Obesity, 2010, 34, 1341-1344.	1.6	85
132	Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietaryâ€induced obesity and insulin resistance. Diabetes, Obesity and Metabolism, 2010, 12, 891-899.	2.2	135
133	The impact of dietary energy intake on cognitive aging. Frontiers in Aging Neuroscience, 2010, 2, 5.	1.7	71
134	GLP-1 Receptor Stimulation Reduces Amyloid-Î² Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 1205-1219.	1.2	273
135	Incretin Analogues that have been Developed to Treat Type 2 Diabetes Hold Promise as a Novel Treatment Strategy for Alzheimers Disease. Recent Patents on CNS Drug Discovery, 2010, 5, 109-117.	0.9	94
136	Gut-Brain Communications: Not the Same at All Ages. Endocrinology, 2010, 151, 852-854.	1.4	1
137	Targeting Î²-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4206-4216.	1.8	101
138	Pleiotropic Actions of the Incretin Hormones. Vitamins and Hormones, 2010, 84, 21-79.	0.7	40
140	Chronic treatment of exendin-4 affects cell proliferation and neuroblast differentiation in the adult mouse hippocampal dentate gyrus. Neuroscience Letters, 2010, 486, 38-42.	1.0	29
141	Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides. Progress in Neurobiology, 2010, 92, 442-462.	2.8	114
142	New roles for insulin-like hormones in neuronal signalling and protection: New hopes for novel treatments of Alzheimerâ€™s disease?. Neurobiology of Aging, 2010, 31, 1495-1502.	1.5	87
143	Val8-glucagon-like peptide-1 protects against AÎ²1â€“40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience, 2010, 170, 1239-1248.	1.1	90
144	Intraocular cellâ€based production of glucagonâ€like peptideâ€1 in the anterior chamber. Acta Ophthalmologica, 2010, 88, e348-9.	0.6	5
145	The Role of GLP-1 in Neuronal Activity and Neurodegeneration. Vitamins and Hormones, 2010, 84, 331-354.	0.7	61
146	Incretin-Based Therapy and Type 2 Diabetes. Vitamins and Hormones, 2010, 84, 389-413.	0.7	20
147	Neuroprotective properties of GLP-1: theoretical and practical applications. Current Medical Research and Opinion, 2011, 27, 547-558.	0.9	125

#	Article	IF	Citations
148	Insulin dysfunction and allostatic load in bipolar disorder. Expert Review of Neurotherapeutics, 2011, 11, 1017-1028.	1.4	54
149	Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochemical Society Transactions, 2011, 39, 891-897.	1.6	142
150	The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2011, 31, 6587-6594.	1.7	559
151	Cardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptideâ€“1-Based Therapies. American Journal of Medicine, 2011, 124, S35-S53.	0.6	59
152	Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes. Behavioural Brain Research, 2011, 220, 30-41.	1.2	175
153	Bidirectional metabolic regulation of neurocognitive function. Neurobiology of Learning and Memory, 2011, 96, 507-516.	1.0	54
154	Neuroprotective effect of intravitreal cellâ€based glucagonâ€like peptideâ€1 production in the optic nerve crush model. Acta Ophthalmologica, 2011, 89, e320-6.	0.6	29
155	Incretin effect: GLP-1, GIP, DPP4. Diabetes Research and Clinical Practice, 2011, 93, S32-S36.	1.1	72
156	Gut Hormones Restrict Neurodegeneration in Parkinsonâ€™s Disease. , 2011, , .		3
159	Protective Roles of the Incretin Hormones Glucagon-Like Peptide-1 and Glucose-Dependent Insolinotropic Polypeptide Hormones in Neurodegeneration. , 0, , .		0
160	The Promise of Neuroprotective Agents in Parkinson?s Disease. Frontiers in Neurology, 2011, 2, 68.	1.1	94
161	INTRAVITREAL CELL-BASED PRODUCTION OF GLUCAGON-LIKE PEPTIDE-1. Retina, 2011, 31, 785-789.	1.0	8
162	Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. British Journal of Pharmacology, 2011, 164, 1410-1420.	2.7	63
163	The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nature Reviews Neuroscience, 2011, 12, 73-87.	4.9	240
164	Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Provides Neuroprotection in Mice Transient Focal Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 1696-1705.	2.4	170
165	Update on incretin hormones. Annals of the New York Academy of Sciences, 2011, 1243, E55-74.	1.8	95
166	Peripheral Glucagon-like Peptide-1 (GLP-1) and Satiation. Physiology and Behavior, 2011, 105, 71-76.	1.0	55
167	The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. European Journal of Pharmacology, 2011, 650, 249-255.	1.7	122

#	Article	IF	Citations
168	Third intracellular loop of glucagon like-peptide-1 receptor is coupled with endogenous mono-ADP-ribosyltransferase â€" Novel type of receptor regulation?. European Journal of Pharmacology, 2011, 666, 35-42.	1.7	3
169	Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes. Expert Opinion on Therapeutic Targets, 2011, 15, 1153-1162.	1.5	30
170	Decreased Glucagon-Like Peptide-1 Receptor Immunoreactivity in the Dentate Granule Cell Layer from Adult in the Gerbil Hippocampus. Cellular and Molecular Neurobiology, 2011, 31, 345-350.	1.7	5
171	Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Therapy, 2011, 2, 101-121.	1.2	98
172	Therapeutic concentrations of glucagon-like peptide-1 in cerebrospinal fluid following cell-based delivery into the cerebral ventricles of cats. Fluids and Barriers of the CNS, 2011, 8, 18.	2.4	13
173	Novel GLPâ€1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. Journal of Neuroscience Research, 2011, 89, 481-489.	1.3	178
174	Ischemiaâ€induced changes in glucagonâ€like peptideâ€1 receptor and neuroprotective effect of its agonist, exendinâ€4, in experimental transient cerebral ischemia. Journal of Neuroscience Research, 2011, 89, 1103-1113.	1.3	107
175	Discovery of potent dipeptidyl peptidase IV inhibitors derived from Î²-aminoamides bearing substituted [1,2,3]-triazolopiperidines for the treatment of type 2 diabetes. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1731-1735.	1.0	24
176	The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist. Expert Review of Endocrinology and Metabolism, 2011, 6, 513-525.	1.2	5
177	Beneficial Effects of Exendin-4 on Experimental Polyneuropathy in Diabetic Mice. Diabetes, 2011, 60, 2397-2406.	0.3	89
178	Intravitreal Injection of Exendin-4 Analogue Protects Retinal Cells in Early Diabetic Rats. , 2011, 52, 278.		74
179	Therapy in the Early Stage: Incretins. Diabetes Care, 2011, 34, S264-S271.	4.3	89
180	Roux-en-Y gastric bypass surgery changes food reward in rats. International Journal of Obesity, 2011, 35, 642-651.	1.6	125
181	Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities. Experimental Diabetes Research, 2011, 2011, 1-6.	3.8	29
182	Structural and Molecular Conservation of Glucagon-Like Peptide-1 and Its Receptor Confers Selective Ligand-Receptor Interaction. Frontiers in Endocrinology, 2012, 3, 141.	1.5	31
183	Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in TypeÂ2 diabetic rats. Clinical Science, 2012, 122, 473-483.	1.8	117
184	Tumor Necrosis Factor-Induced Cerebral Insulin Resistance in Alzheimer's Disease Links Numerous Treatment Rationales. Pharmacological Reviews, 2012, 64, 1004-1026.	7.1	65
185	Common variants at 12q14 and 12q24 are associated with hippocampal volume. Nature Genetics, 2012, 44, 545-551.	9.4	212

#	Article	IF	Citations
186	Dietary Fiber, Gut Peptides, and Adipocytokines. Journal of Medicinal Food, 2012, 15, 223-230.	0.8	55
187	Glucagon-Like Peptide-1 Cleavage Product GLP-1(9-36) Amide Rescues Synaptic Plasticity and Memory Deficits in Alzheimer's Disease Model Mice. Journal of Neuroscience, 2012, 32, 13701-13708.	1.7	97
188	Glucagon-Like Peptide 1, Insulin, Sensory Neurons, and Diabetic Neuropathy. Journal of Neuropathology and Experimental Neurology, 2012, 71, 494-510.	0.9	65
191	Intranasal administration of PACAP: Uptake by brain and regional brain targeting with cyclodextrins. Peptides, 2012, 36, 168-175.	1.2	61
192	Evolutionarily Conserved Residues at Glucagon-like Peptide-1 (GLP-1) Receptor Core Confer Ligand-induced Receptor Activation. Journal of Biological Chemistry, 2012, 287, 3873-3884.	1.6	20
193	Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiology of Aging, 2012, 33, 265-276.	1.5	144
194	Neuroprotective and neurotrophic actions of glucagonâ€like peptideâ€1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. British Journal of Pharmacology, 2012, 166, 1586-1599.	2.7	200
195	GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology, 2012, 8, 728-742.	4.3	971
196	Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neuroscience, 2012, 13, 33.	0.8	372
197	Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide are neuroprotective on cultured and mast cell co-cultured rat myenteric neurons. BMC Gastroenterology, 2012, 12, 30.	0.8	24
198	GLP-1 secretion by microglial cells and decreased CNS expression in obesity. Journal of Neuroinflammation, 2012, 9, 276.	3.1	82
199	Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain. Brain Research, 2012, 1473, 204-213.	1.1	39
200	Polyunsaturated fatty acids as putative cognitive enhancers. Medical Hypotheses, 2012, 79, 456-461.	0.8	32
201	Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection. CNS Drugs, 2012, 26, 871-882.	2.7	156
202	Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Medicine, 2012, 10, 92.	2.3	24
203	Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis. PLoS ONE, 2012, 7, e32008.	1.1	101
204	Intracerebroventricular Injection of Encapsulated Human Mesenchymal Cells Producing Glucagon-Like Peptide 1 Prolongs Survival in a Mouse Model of ALS. PLoS ONE, 2012, 7, e36857.	1.1	54
205	Fertility and Pregnancy-Associated ÃŸ-Cell Proliferation in Mice Deficient in Proglucagon-Derived Peptides. PLoS ONE, 2012, 7, e43745.	1.1	13

#	Article	IF	Citations
206	Self-assembling glucagon-like peptide 1-mimetic peptide amphiphiles for enhanced activity and proliferation of insulin-secreting cells. Acta Biomaterialia, 2012, 8, 1685-1692.	4.1	35
207	Intranasal delivery of biologics to the central nervous system. Advanced Drug Delivery Reviews, 2012, 64, 614-628.	6.6	854
208	Drug delivery to the brain in Alzheimer's disease: Consideration of the bloodâ€“brain barrier. Advanced Drug Delivery Reviews, 2012, 64, 629-639.	6.6	144
209	Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats. Brain Research, 2012, 1427, 23-34.	1.1	59
210	Acute administration of GLP-1 receptor agonists induces hypolocomotion but not anxiety in mice. Acta Neuropsychiatrica, 2012, 24, 296-300.	1.0	17
211	Role of the bloodâ€“brain barrier in the evolution of feeding and cognition. Annals of the New York Academy of Sciences, 2012, 1264, 13-19.	1.8	72
212	Functional importance of GLP-1 receptor species and expression levels in cell lines. Regulatory Peptides, 2012, 175, 21-29.	1.9	29
213	Cognitive and neuronal systems underlying obesity. Physiology and Behavior, 2012, 106, 337-344.	1.0	65
214	Exendin-4 decreases amphetamine-induced locomotor activity. Physiology and Behavior, 2012, 106, 574-578.	1.0	74
215	Glucagon like-peptide-1 receptor is covalently modified by endogenous mono-ADP-ribosyltransferase. Molecular Biology Reports, 2012, 39, 4375-4381.	1.0	1
216	Combining <scp>GLP</scp>â€1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes, Obesity and Metabolism, 2013, 15, 3-14.	2.2	56
217	Berberine chloride improved synaptic plasticity in STZ induced diabetic rats. Metabolic Brain Disease, 2013, 28, 421-428.	1.4	30
218	Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. International Journal of Clinical Pharmacy, 2013, 35, 159-172.	1.0	58
219	Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney. BMC Nephrology, 2013, 14, 98.	0.8	63
220	Fructus Gardenia (Gardenia jasminoides J. Ellis) phytochemistry, pharmacology of cardiovascular, and safety with the perspective of new drugs development. Journal of Asian Natural Products Research, 2013, 15, 94-110.	0.7	79
221	The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid-Î² Plaque and Glial Pathology in a Mouse Model of Alzheimerâ€™s Disease. NeuroMolecular Medicine, 2013, 15, 102-114.	1.8	134
222	Is obesity a brain disease?. Neuroscience and Biobehavioral Reviews, 2013, 37, 2489-2503.	2.9	99
223	Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age, 2013, 35, 1621-1636.	3.0	83

#	Article	IF	Citations
224	Growth hormone (GH) and brain trauma. Hormones and Behavior, 2013, 63, 331-344.	1.0	76
225	Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. Journal of Pharmacy and Pharmacology, 2013, 65, 1773-1784.	1.2	123
226	<scp>DPP</scp>4â€inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by highâ€fat diet consumption. European Journal of Neuroscience, 2013, 37, 839-849.	1.2	151
227	Unique roles of glucagon and glucagon-like peptides: Parallels in understanding the functions of adipokinetic hormones in stress responses in insects. Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology, 2013, 164, 91-100.	0.8	49
228	Liraglutide protects against amyloid-Î² protein-induced impairment of spatial learning and memory in rats. Neurobiology of Aging, 2013, 34, 576-588.	1.5	114
229	Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice. Brain Research, 2013, 1517, 104-113.	1.1	49
230	Exendin-4 ameliorates renal ischemia-reperfusion injury in the rat. Journal of Surgical Research, 2013, 185, 825-832.	0.8	26
231	The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant?. Current Opinion in Pharmacology, 2013, 13, 964-969.	1.7	77
232	Associations Between Obesity and Comorbid Mental Health, Developmental, and Physical Health Conditions. Academic Pediatrics, 2013, 13, 1-2.	1.0	2
233	Crosstalk between diabetes and brain: Glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 527-541.	1.8	113
234	Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action. Cell Metabolism, 2013, 17, 819-837.	7.2	1,088
235	Exendin (5-39), an antagonist of GLP-1 receptor, modulates synaptic transmission via glutamate uptake in the dentate gyrus. Brain Research, 2013, 1505, 1-10.	1.1	16
236	DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. Journal of Endocrinology, 2013, 218, 1-11.	1.2	197
237	Saxagliptin: A dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. Neuropharmacology, 2013, 72, 291-300.	2.0	158
238	The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders. Behavioural Brain Research, 2013, 237, 164-171.	1.2	79
239	Preproglucagon (PPG) neurons innervate neurochemicallyidentified autonomic neurons in the mouse brainstem. Neuroscience, 2013, 229, 130-143.	1.1	52
240	Therapeutic Potential of N-Acetyl-Glucagon-Like Peptide-1 in Primary Motor Neuron Cultures Derived From Non-Transgenic and SOD1-G93A ALS Mice. Cellular and Molecular Neurobiology, 2013, 33, 347-357.	1.7	24
241	Minireview: Signal Bias, Allosterism, and Polymorphic Variation at the GLP-1R: Implications for Drug Discovery. Molecular Endocrinology, 2013, 27, 1234-1244.	3.7	30

#	Article	IF	Citations
242	Protection of Glucagon-Like Peptide-1 in Cisplatin-Induced Renal Injury Elucidates Gut-Kidney Connection. Journal of the American Society of Nephrology: JASN, 2013, 24, 2034-2043.	3.0	70
243	Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism. Frontiers in Endocrinology, 2013, 4, 73.	1.5	36
244	Cell-based delivery of glucagon-like peptide-1 using encapsulated mesenchymal stem cells. Journal of Microencapsulation, 2013, 30, 315-324.	1.2	12
245	Medicinal Chemistry of Glucagon-Like Peptide Receptor Agonists. Progress in Medicinal Chemistry, 2013, 52, 45-96.	4.1	13
246	Incretin-Based Therapy for Type 2 Diabetes Mellitus. American Journal of Therapeutics, 2013, 20, 384-393.	0.5	7
247	New therapeutic strategy for Alzheimer's disease using antidiabetes agents. Journal of Diabetes Investigation, 2013, 4, 152-153.	1.1	0
248	Glucagonâ€like peptideâ€1 in the rat brain: Distribution of expression and functional implication. Journal of Comparative Neurology, 2013, 521, 2235-2261.	0.9	90
249	Obesityâ€Related Hormones in Lowâ€Income Preschoolâ€Age Children: Implications for School Readiness. Mind, Brain, and Education, 2013, 7, 246-255.	0.9	12
250	Val⁸â€GLPâ€1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid Î² peptide in rats. Journal of Neuroscience Research, 2013, 91, 568-577.	1.3	24
251	Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. Cell Death and Disease, 2013, 4, e612-e612.	2.7	64
252	Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E1105-E1117.	1.8	22
253	Alzheimerâ€™s disease and insulin resistance: translating basic science into clinical applications. Journal of Clinical Investigation, 2013, 123, 531-539.	3.9	285
254	Exendin-4 Induces Cell Adhesion and Differentiation and Counteracts the Invasive Potential of Human Neuroblastoma Cells. PLoS ONE, 2013, 8, e71716.	1.1	17
255	A Novel Glucagon-Related Peptide (GCRP) and Its Receptor GCRPR Account for Coevolution of Their Family Members in Vertebrates. PLoS ONE, 2013, 8, e65420.	1.1	28
256	Pleiotropic Effects of an Incretin Hormone. Journal of Korean Diabetes, 2013, 14, 120.	0.1	0
257	The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation, 2014, 124, 4473-4488.	3.9	617
258	Transcriptome Analysis of the Hippocampus in Novel Rat Model of Febrile Seizures. PLoS ONE, 2014, 9, e95237.	1.1	19
259	Detection of Impaired Cognitive Function in Rat with Hepatosteatosis Model and Improving Effect of GLP-1 Analogs (Exenatide) on Cognitive Function in Hepatosteatosis. Scientific World Journal, The, 2014, 2014, 1-5.	0.8	6

#	Article	IF	Citations
260	Gut-brain peptides in corticostriatal-limbic circuitry and alcohol use disorders. Frontiers in Neuroscience, 2014, 8, 288.	1.4	22
261	Treatment of Insulin Resistance in the Neurodegeneration. Recent Patents on CNS Drug Discovery, 2014, 9, 54-63.	0.9	4
262	Exendin-4 effects on islet volume and number in the mouse pancreas. Bratislava Medical Journal, 2014, 115, 502-507.	0.4	1
263	GLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action. Physiology, 2014, 29, 108-121.	1.6	18
264	Identification and Characterization of GLP-1 Receptorâ€“Expressing Cells Using a New Transgenic Mouse Model. Diabetes, 2014, 63, 1224-1233.	0.3	345
265	Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonistâ€”protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. BMJ Open, 2014, 4, e004158.	0.8	20
266	Discovery of		

#	Article	IF	Citations
278	Neuroprotective and antiâ€apoptotic effects of liraglutide on <scp>SH</scp>â€<scp>SY</scp>5Y cells exposed to methylglyoxal stress. Journal of Neurochemistry, 2014, 128, 459-471.	2.1	129
279	Dipeptidyl peptidase-4 inhibition by Pterocarpus marsupium and Eugenia jambolana ameliorates streptozotocin induced Alzheimer's disease. Behavioural Brain Research, 2014, 267, 55-65.	1.2	45
280	What are the priorities in Parkinson's disease clinical research? A focus on motor complications, gait and cognition. Neurodegenerative Disease Management, 2014, 4, 127-136.	1.2	2
281	Type 2 Diabetes and Cognitive Impairment. Journal of Geriatric Psychiatry and Neurology, 2014, 27, 47-55.	1.2	60
282	Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. Journal of Endocrinology, 2014, 221, T31-T41.	1.2	224
283	Incretins and Amylin: Neuroendocrine Communication Between the Gut, Pancreas, and Brain in Control of Food Intake and Blood Glucose. Annual Review of Nutrition, 2014, 34, 237-260.	4.3	73
284	Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. Neuropharmacology, 2014, 86, 241-258.	2.0	130
285	Inflammation, Defective Insulin Signaling, and Mitochondrial Dysfunction as Common Molecular Denominators Connecting Type 2 Diabetes to Alzheimer Disease. Diabetes, 2014, 63, 2262-2272.	0.3	462
286	Incretins: Their physiology and application in the treatment of diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2014, 30, 354-371.	1.7	84
287	Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases. Biochemical Society Transactions, 2014, 42, 593-599.	1.6	91
288	Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice. Peptides, 2014, 61, 38-47.	1.2	40
289	MOLECULAR EVOLUTION OF GPCRS: GLP1/GLP1 receptors. Journal of Molecular Endocrinology, 2014, 52, T15-T27.	1.1	18
290	Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. Journal of Endocrinology, 2014, 221, T1-T16.	1.2	191
291	Diabetes drugs and neurological disorders: new views and therapeutic possibilities. Lancet Diabetes and Endocrinology,the, 2014, 2, 256-262.	5.5	121
292	Lixisenatide rescues spatial memory and synaptic plasticity from amyloid Î² protein-induced impairments in rats. Neuroscience, 2014, 277, 6-13.	1.1	83
293	How does brain insulin resistance develop in Alzheimer's disease?. Alzheimer's and Dementia, 2014, 10, S26-32.	0.4	261
294	Dipeptidyl peptidase-IV inhibition prevents bloodâ€“retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1454-1463.	1.8	64
295	Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?. Progress in Neurobiology, 2014, 118, 1-18.	2.8	185

#	Article	IF	Citations
296	Exendin-4 promotes the membrane trafficking of the AMPA receptor GluR1 subunit and ADAM10 in the mouse neocortex. Regulatory Peptides, 2014, 190-191, 1-11.	1.9	30
297	Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease Ã¢â‚¬â€œ How Anti-Diabetics Could be a Solution for Dementia. Frontiers in Endocrinology, 2014, 5, 110.	1.5	74
298	Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2014, 4, 337-344.	1.5	206
299	Diabetes as a disease of accelerated cognitive aging: role of diabetes interventions and implications for patient care. Diabetes Management, 2014, 4, 63-69.	0.5	0
300	Central Nervous System Delivery of Intranasal Insulin: Mechanisms of Uptake and Effects on Cognition. Journal of Alzheimer's Disease, 2015, 47, 715-728.	1.2	100
301	Anorexigenic Lipopeptides Ameliorate Central Insulin Signaling and Attenuate Tau Phosphorylation in Hippocampi of Mice with Monosodium Glutamate-Induced Obesity. Journal of Alzheimer's Disease, 2015, 45, 823-835.	1.2	39
302	Upregulation of D site of albumin promoter binding protein in the brain of patients with intractable epilepsy. Molecular Medicine Reports, 2015, 11, 2486-2492.	1.1	3
303	DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice. Cardiovascular Diabetology, 2015, 14, 54.	2.7	56
304	Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. Journal of Neurochemistry, 2015, 135, 1203-1217.	2.1	76
305	Diabetes and Stem Cell Function. BioMed Research International, 2015, 2015, 1-16.	0.9	26
306	GLP-1 based therapeutics: simultaneously combating T2DM and obesity. Frontiers in Neuroscience, 2015, 9, 92.	1.4	95
307	Modulation of Hippocampal Neural Plasticity by Glucose-Related Signaling. Neural Plasticity, 2015, 2015, 1-10.	1.0	67
308	Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide. World Journal of Diabetes, 2015, 6, 807.	1.3	62
309	Nose-to-Brain delivery of insulin for Alzheimerâ€™s disease. ADMET and DMPK, 2015, 3, .	1.1	23
310	Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Experimental and Molecular Medicine, 2015, 47, e149-e149.	3.2	225
311	Septal Glucagon-Like Peptide 1 Receptor Expression Determines Suppression of Cocaine-Induced Behavior. Neuropsychopharmacology, 2015, 40, 1969-1978.	2.8	67
312	GLP-1 and Exendin-4 Transiently Enhance GABAA Receptorâ€“Mediated Synaptic and Tonic Currents in Rat Hippocampal CA3 Pyramidal Neurons. Diabetes, 2015, 64, 79-89.	0.3	79
313	Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimerâ€™s Disease and Other Neurodegenerative Diseases. CNS Drugs, 2015, 29, 1023-1039.	2.7	72

#	Article	IF	Citations
314	PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 309, R795-R804.	0.9	64
315	Hacia un manejo integral del paciente con diabetes y obesidad. Posicionamiento de la SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC. Revista Clinica Espanola, 2015, 215, 505-514.	0.2	12
316	Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Molecular Metabolism, 2015, 4, 718-731.	3.0	323
317	Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture. Diabetes, 2015, 64, 317-326.	0.3	65
318	Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1. Open Heart, 2015, 2, e000205.	0.9	33
319	Stem cells for amyotrophic lateral sclerosis modeling and therapy: Myth or fact?. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 197-211.	1.1	18
320	Intranasal Glucagon. Journal of Diabetes Science and Technology, 2015, 9, 38-43.	1.3	30
321	Sitagliptin, a dipeptidyl peptidaseâ€4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline. Diabetes, Obesity and Metabolism, 2015, 17, 403-413.	2.2	116
322	Sitagliptin attenuates transient cerebral ischemia/reperfusion injury in diabetic rats: Implication of the oxidativeâ€“inflammatoryâ€“apoptotic pathway. Life Sciences, 2015, 126, 81-86.	2.0	58
323	Age-Related Decrease in Glucagon-Like Peptide-1 in Mouse Prefrontal Cortex but Not in Hippocampus Despite the Preservation of Its Receptor. American Journal of BioScience, 2015, 3, 11.	0.3	7
324	Peptides and aging: Their role in anorexia and memory. Peptides, 2015, 72, 112-118.	1.2	22
325	Liraglutide Promotes Cortical Neurite Outgrowth via the MEKâ€“ERK Pathway. Cellular and Molecular Neurobiology, 2015, 35, 987-993.	1.7	19
326	Molecular Mechanisms of Geniposide and Genipin Against Alzheimerâ€™s Disease. , 2015, , 221-227.		0
327	Expression and Distribution of Glucagon-Like Peptide-1 Receptor mRNA, Protein and Binding in the Male Nonhuman Primate (Macaca mulatta) Brain. Endocrinology, 2015, 156, 255-267.	1.4	139
328	Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment. Clinical Interventions in Aging, 2015, 10, 549.	1.3	209
329	The non-glycemic effects of incretin therapies on cardiovascular outcomes, cognitive function and bone health. Expert Review of Endocrinology and Metabolism, 2015, 10, 101-114.	1.2	6
330	Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Reduces Alzheimer Disease-Associated Tau Hyperphosphorylation in the Hippocampus of Rats with Type 2 Diabetes. Journal of Investigative Medicine, 2015, 63, 267-272.	0.7	69
331	Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases. AAPS Journal, 2015, 17, 780-787.	2.2	151

#	Article	IF	Citations
333	GLP-1 receptor agonists have a sustained stimulatory effect on corticosterone release after chronic treatment. Acta Neuropsychiatrica, 2015, 27, 25-32.	1.0	23
334	Neuronal stress signaling and eIF2Î± phosphorylation as molecular links between Alzheimer's disease and diabetes. Progress in Neurobiology, 2015, 129, 37-57.	2.8	65
335	Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes. Diabetes, 2016, 65, 172-187.	0.3	168
336	Mice Lacking Free Fatty Acid Receptor 1 (GPR40/FFAR1) are Protected Against Conjugated Linoleic Acid-Induced Fatty Liver but Develop Inflammation and Insulin Resistance in the Brain. Cellular Physiology and Biochemistry, 2015, 35, 2272-2284.	1.1	27
337	Restoration of Cerebral and Systemic Microvascular Architecture in <scp>APP</scp>/<scp>PS</scp>1 Transgenic Mice Following Treatment with Liraglutide^{â„¢}. Microcirculation, 2015, 22, 133-145.	1.0	40
338	A Novel GLP1 Receptor Interacting Protein ATP6ap2 Regulates Insulin Secretion in Pancreatic Beta Cells. Journal of Biological Chemistry, 2015, 290, 25045-25061.	1.6	25
339	Position statement of the SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC. Revista Clínica Espanõla, 2015, 215, 505-514.	0.3	3
340	Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/Î²-endorphin pathway. Pharmacological Research, 2015, 102, 276-285.	3.1	32
341	New Horizons in the Management of Alzheimer Disease. Journal of the American Medical Directors Association, 2015, 16, 1-5.	1.2	27
342	Hippocampal GLP-1 Receptors Influence Food Intake, Meal Size, and Effort-Based Responding for Food through Volume Transmission. Neuropsychopharmacology, 2015, 40, 327-337.	2.8	124
343	Obesity-associated biomarkers and executive function in children. Pediatric Research, 2015, 77, 143-147.	1.1	81
344	Glucagon-Like Peptide 1, Neuroprotection and Neurodegenerative Disorders. Journal of Biomolecular Research & Therapeutics, 2016, 5, .	0.2	0
345	The Endocrine Regulation of Stem Cells: Physiological Importance and Pharmacological Potentials for Cell-Based Therapy. Current Stem Cell Research and Therapy, 2016, 11, 19-34.	0.6	17
346	In Alzheimerâ€™s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Frontiers in Aging Neuroscience, 2016, 8, 108.	1.7	282
347	Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on Î²-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimerâ€™s Disease. PLoS ONE, 2016, 11, e0158205.	1.1	39
348	Trophic Factors in the Therapeutic Challenge Against ALS: Current Research Directions. , 2016, , .		1
349	Neuroenergetics of traumatic brain injury. Concussion, 2016, 1, CNC9.	1.2	9
350	De Novo Arteriovenous Malformation Growth Secondary to Implantation of Genetically Modified Allogeneic Mesenchymal Stem Cells in the Brain. Neurosurgery, 2016, 78, E596-E600.	0.6	16

#	Article	IF	Citations
351	Exenatide enhances cognitive performance and upregulates neurotrophic factor gene expression levels in diabetic mice. Fundamental and Clinical Pharmacology, 2016, 30, 376-384.	1.0	34
352	Effect of Liraglutide on Corneal Kindling Epilepsy Induced Depression and Cognitive Impairment in Mice. Neurochemical Research, 2016, 41, 1741-1750.	1.6	25
353	Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3Î² pathway in an amyloid Î² protein induced alzheimer disease mouse model. European Journal of Pharmacology, 2016, 783, 23-32.	1.7	85
354	GLP-1 and weight loss: unraveling the diverse neural circuitry. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 310, R885-R895.	0.9	172
355	The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia. Journal of Neuroinflammation, 2016, 13, 204.	3.1	35
356	Combination of Sitagliptin and Insulin against Type 2 Diabetes Mellitus with Neuropathy in Rats: Neuroprotection and Role of Oxidative and Inflammation Stress. Pharmacology, 2016, 98, 242-250.	0.9	13
357	Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes. Frontiers in Neuroendocrinology, 2016, 42, 76-92.	2.5	51
358	Potentials of incretinâ€based therapies in dementia and stroke in type 2 diabetes mellitus. Journal of Diabetes Investigation, 2016, 7, 5-16.	1.1	40
359	Glucagon-Like Peptide-1 and Its Class B G Proteinâ€“Coupled Receptors: A Long March to Therapeutic Successes. Pharmacological Reviews, 2016, 68, 954-1013.	7.1	252
360	The physiological role of the brain GLP-1 system in stress. Cogent Biology, 2016, 2, 1229086.	1.7	35
361	Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide analogues as novel treatments for Alzheimerâ€™s and Parkinsonâ€™s disease. Cardiovascular Endocrinology, 2016, 5, 93-98.	0.8	24
362	Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. Reviews in the Neurosciences, 2016, 27, 689-711.	1.4	27
363	Role of metabolism in neurodegenerative disorders. Metabolism: Clinical and Experimental, 2016, 65, 1376-1390.	1.5	158
364	Mechanisms for the cardiovascular effects of glucagon-like peptide-1. Acta Physiologica, 2016, 216, 277-313.	1.8	22
365	G protein-coupled receptors as new therapeutic targets for type 2 diabetes. Diabetologia, 2016, 59, 229-233.	2.9	56
366	Exendin-4, a glucagon-like peptide 1 receptor agonist, protects against amyloid-Î² peptide-induced impairment of spatial learning and memory in rats. Physiology and Behavior, 2016, 159, 72-79.	1.0	19
367	Neurochemical modulation involved in the beneficial effect of liraglutide, GLP-1 agonist on PTZ kindling epilepsy-induced comorbidities in mice. Molecular and Cellular Biochemistry, 2016, 415, 77-87.	1.4	41
368	Neurobehavioral effects of liraglutide and sitagliptin in experimental models. European Journal of Pharmacology, 2016, 774, 64-70.	1.7	34

#	Article	IF	Citations
369	The inactivation of extracellular signal-regulated kinase by glucagon-like peptide-1 contributes to neuroprotection against oxidative stress. Neuroscience Letters, 2016, 616, 105-110.	1.0	8
370	The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discovery Today, 2016, 21, 802-818.	3.2	247
371	Glucagon-Like Peptide-1 Strengthens the Barrier Integrity in Primary Cultures of Rat Brain Endothelial Cells Under Basal and Hyperglycemia Conditions. Journal of Molecular Neuroscience, 2016, 59, 211-219.	1.1	34
372	Intranasal administration of Exendin-4 antagonizes AÎ²31â€“35-induced disruption of circadian rhythm and impairment of learning and memory. Aging Clinical and Experimental Research, 2016, 28, 1259-1266.	1.4	25
373	Albiglutide: Is a better hope against diabetes mellitus?. Biomedicine and Pharmacotherapy, 2016, 77, 120-128.	2.5	13
374	Obestatin promotes proliferation and survival of adult hippocampal progenitors and reduces amyloid-Î²-induced toxicity. Molecular and Cellular Endocrinology, 2016, 422, 18-30.	1.6	20
375	Therapeutic strategies for Alzheimer's disease in clinical trials. Pharmacological Reports, 2016, 68, 127-138.	1.5	357
376	The Role of Essential Fatty Acids in Anorexia Nervosa and Obesity. Critical Reviews in Food Science and Nutrition, 2016, 56, 2021-2035.	5.4	10
377	Hippocampus Contributions to Food Intake Control: Mnemonic, Neuroanatomical, and Endocrine Mechanisms. Biological Psychiatry, 2017, 81, 748-756.	0.7	181
378	Delayed administration of the GLP-1 receptor agonist liraglutide improves metabolic and functional recovery after cerebral ischemia in rats. Neuroscience Letters, 2017, 641, 1-7.	1.0	23
379	Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects. Behavioural Brain Research, 2017, 321, 157-169.	1.2	77
380	Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core. Journal of Medicinal Chemistry, 2017, 60, 1611-1616.	2.9	10
381	Liraglutide attenuates partial warm ischemia-reperfusion injury in rat livers. Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390, 311-319.	1.4	14
382	Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications. Expert Review of Clinical Pharmacology, 2017, 10, 409-428.	1.3	128
383	Islet amyloid polypeptide: Another key molecule in Alzheimerâ€™s pathogenesis?. Progress in Neurobiology, 2017, 153, 100-120.	2.8	64
384	No cognitiveâ€enhancing effect of <scp>GLP</scp>â€1 receptor agonism in antipsychoticâ€treated, obese patients with schizophrenia. Acta Psychiatrica Scandinavica, 2017, 136, 52-62.	2.2	36
385	Bariatric surgery may reduce the risk of Alzheimerâ€™s diseases through GLP-1 mediated neuroprotective effects. Medical Hypotheses, 2017, 104, 4-9.	0.8	14
386	Hippocampal Ghrelin-positive neurons directly project to arcuate hypothalamic and medial amygdaloid nuclei. Could they modulate food-intake?. Neuroscience Letters, 2017, 653, 126-131.	1.0	15

#	Article	IF	Citations
387	Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2239-2258.	1.0	19
388	GLP-1 analogue CJC-1131 prevents amyloid Î² protein-induced impirments of spatial memory and synaptic plasticity in rats. Behavioural Brain Research, 2017, 326, 237-243.	1.2	10
389	A ketogenic diet rescues hippocampal memory defects in a mouse model of Kabuki syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 125-130.	3.3	102
390	Interactions between metabolic, reward and cognitive processes in appetite control: Implications for novel weight management therapies. Journal of Psychopharmacology, 2017, 31, 1460-1474.	2.0	61
391	Autocrine Interleukin-10 Mediates Glucagon-Like Peptide-1 Receptor-Induced Spinal Microglial Î²-Endorphin Expression. Journal of Neuroscience, 2017, 37, 11701-11714.	1.7	57
392	Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues. Diabetes Care, 2017, 40, 1522-1529.	4.3	50
393	Glucagonâ€like peptideâ€1 cleavage product GLPâ€1 (9â€36) amide enhances hippocampal longâ€term synaptic plasticity in correlation with suppression of Kv4.2 expression and eEF2 phosphorylation. Hippocampus, 2017, 27, 1264-1274.	0.9	11
394	Treatment with a GLPâ€1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. European Neuropsychopharmacology, 2017, 27, 1153-1162.	0.3	49
395	DPP4 Inhibitors Can Be a Drug of Choice for Type 3 Diabetes: A Mini Review. American Journal of Alzheimer's Disease and Other Dementias, 2017, 32, 444-451.	0.9	16
396	Liraglutide ameliorates cardiotoxicity induced by doxorubicin in rats through the Akt/GSK-3Î² signaling pathway. Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390, 1145-1153.	1.4	19
397	A New Treatment Strategy for Parkinson's Disease through the Gutâ€“Brain Axis. Cell Transplantation, 2017, 26, 1560-1571.	1.2	111
398	Intestinal Incretins and the Regulation of Bone Physiology. Advances in Experimental Medicine and Biology, 2017, 1033, 13-33.	0.8	23
399	Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes. Trends in Endocrinology and Metabolism, 2017, 28, 88-103.	3.1	88
400	Lixisenatide attenuates the detrimental effects of amyloid Î² protein on spatial working memory and hippocampal neurons in rats. Behavioural Brain Research, 2017, 318, 28-35.	1.2	30
401	Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimerâ€™s disease pathology. Expert Review of Neurotherapeutics, 2017, 17, 59-75.	1.4	29
402	Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. Journal of Affective Disorders, 2017, 207, 114-120.	2.0	110
403	Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells. Scientific Reports, 2017, 7, 16158.	1.6	44
404	Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke. Experimental Neurobiology, 2017, 26, 227-239.	0.7	38

#	Article	IF	Citations
405	Role of Incretin Axis in Inflammatory Bowel Disease. Frontiers in Immunology, 2017, 8, 1734.	2.2	43
406	Gut to Brain Dysbiosis: Mechanisms Linking Western Diet Consumption, the Microbiome, and Cognitive Impairment. Frontiers in Behavioral Neuroscience, 2017, 11, 9.	1.0	216
407	The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain. International Journal of Molecular Sciences, 2017, 18, 2493.	1.8	52
408	Gastrointestinal hormones in regulation of memory. Peptides, 2018, 102, 16-25.	1.2	22
409	Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats. Journal of Psychopharmacology, 2018, 32, 578-590.	2.0	28
410	Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?. Neuropharmacology, 2018, 136, 335-342.	2.0	20
411	Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimerâ€™s disease. Neuropharmacology, 2018, 135, 48-62.	2.0	39
412	Intranasal glucagon for hypoglycaemia in diabetic patients. An old dream is becoming reality?. Diabetes, Obesity and Metabolism, 2018, 20, 1812-1816.	2.2	20
413	Augmentation of glucagonâ€like peptideâ€1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure. European Journal of Heart Failure, 2018, 20, 973-977.	2.9	26
414	Intranasally Administered S100A9 Amyloids Induced Cellular Stress, Amyloid Seeding, and Behavioral Impairment in Aged Mice. ACS Chemical Neuroscience, 2018, 9, 1338-1348.	1.7	14
415	Geniposide improves repeated restraint stress-induced depression-like behavior in mice by ameliorating neuronal apoptosis via regulating GLP-1R/AKT signaling pathway. Neuroscience Letters, 2018, 676, 19-26.	1.0	51
416	Characterization of the Glucagonlike Peptide-1 Receptor in Male Mouse Brain Using a Novel Antibody and In Situ Hybridization. Endocrinology, 2018, 159, 665-675.	1.4	90
417	Possible role of DPP4 inhibitors to promote hippocampal neurogenesis in Alzheimerâ€™s disease. Journal of Drug Targeting, 2018, 26, 670-675.	2.1	12
418	Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models. Neuropharmacology, 2018, 136, 251-259.	2.0	126
419	The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a nonâ€human primate model of Alzheimer's disease. Journal of Pathology, 2018, 245, 85-100.	2.1	180
420	Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice. Neurobiology of Aging, 2018, 64, 33-43.	1.5	49
421	Presynaptic GLPâ€1 receptors enhance the depolarizationâ€evoked release of glutamate and GABA in the mouse cortex and hippocampus. BioFactors, 2018, 44, 148-157.	2.6	24
422	Sustained highâ€fat diet modulates inflammation, insulin signalling and cognition in mice and a modified xenin peptide ameliorates neuropathology in a chronic highâ€fat model. Diabetes, Obesity and Metabolism, 2018, 20, 1166-1175.	2.2	49

#	Article	IF	Citations
423	Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world. Biomedicine and Pharmacotherapy, 2018, 97, 1521-1537.	2.5	223
424	Glucagon like peptide-1 (GLP-1) likes Alzheimerâ€™s disease. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 469-475.	1.8	58
425	Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses. Molecular Neurobiology, 2018, 55, 3007-3020.	1.9	73
426	Sitagliptin enhances the neuroprotective effect of pregabalin against pentylenetetrazole-induced acute epileptogenesis in mice: Implication of oxidative, inflammatory, apoptotic and autophagy pathways. Neurochemistry International, 2018, 115, 11-23.	1.9	47
427	Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease. Biochemical and Biophysical Research Communications, 2018, 495, 1034-1040.	1.0	70
428	Oral sodium butyrate impacts brain metabolism and hippocampal neurogenesis, with limited effects on gut anatomy and function in pigs. FASEB Journal, 2018, 32, 2160-2171.	0.2	58
429	Exenatide upregulates gene expression of glucagonâ€like peptideâ€1 receptor and nerve growth factor in streptozotocin/nicotinamideâ€induced diabetic mice. Fundamental and Clinical Pharmacology, 2018, 32, 174-180.	1.0	15
430	Hippocampus ghrelin receptor signaling promotes socially-mediated learned food preference. Neuropharmacology, 2018, 131, 487-496.	2.0	44
431	Nose-to-brain peptide delivery â€“ The potential of nanotechnology. Bioorganic and Medicinal Chemistry, 2018, 26, 2888-2905.	1.4	113
432	A cafeteria diet alters the decision making strategy and metabolic markers in Sprague-Dawley male rats. Applied Animal Behaviour Science, 2018, 199, 35-44.	0.8	3
433	Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy. Acta Neuropathologica, 2018, 135, 95-113.	3.9	38
434	Liraglutide Activates mTORC1 Signaling and AMPA Receptors in Rat Hippocampal Neurons Under Toxic Conditions. Frontiers in Neuroscience, 2018, 12, 756.	1.4	17
435	Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Research Bulletin, 2018, 143, 155-170.	1.4	468
436	Unravelling the role and mechanism of adipokine and gastrointestinal signals in animal models in the nonhomeostatic control of energy homeostasis: Implications for binge eating disorder. European Eating Disorders Review, 2018, 26, 551-568.	2.3	14
437	Fasting enhances extinction retention and prevents the return of fear in humans. Translational Psychiatry, 2018, 8, 214.	2.4	17
438	12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus. Clinical Pharmacology: Advances and Applications, 2018, Volume 10, 141-151.	0.8	17
439	Glucagon-like peptide 1 receptor (GLP-1R) expression by nerve fibres in inflammatory bowel disease and functional effects in cultured neurons. PLoS ONE, 2018, 13, e0198024.	1.1	18
440	The role of milk fat globule membranes in behavior and cognitive function using a suckling rat pup supplementation model. Journal of Nutritional Biochemistry, 2018, 58, 131-137.	1.9	30

#	Article	IF	Citations
441	Impact of Earlyâ€Life Weight Status on Cognitive Abilities in Children. Obesity, 2018, 26, 1088-1095.	1.5	23
442	Pharmacological and Nonpharmacological Interventions for Cognitive Impairment and Dementia Related to Type 2 Diabetes and Metabolic Disturbances in Aging. , 2018, , 231-253.		0
443	The role of the GLP-1/GLP-1R signaling pathway in regulating seizure susceptibility in rats. Brain Research Bulletin, 2018, 142, 47-53.	1.4	7
444	Engineered commensal bacteria prevent systemic inflammation-induced memory impairment and amyloidogenesis via producing GLP-1. Applied Microbiology and Biotechnology, 2018, 102, 7565-7575.	1.7	34
445	Inhibition of DPP4 enhances inhibitory synaptic transmission through activating the GLP-1/GLP-1R signaling pathway in a rat model of febrile seizures. Biochemical Pharmacology, 2018, 156, 78-85.	2.0	20
446	A New Perspective in Utilizing MMP-9 as a Therapeutic Target for Alzheimerâ€™s Disease and Type 2 Diabetes Mellitus. Journal of Alzheimer's Disease, 2018, 64, 1-16.	1.2	36
447	Drug development for Alzheimerâ€™s disease: review. Journal of Drug Targeting, 2019, 27, 164-173.	2.1	60
448	Diabetes Therapies for Dementia. Current Neurology and Neuroscience Reports, 2019, 19, 58.	2.0	20
449	Therapeutic Use of Intranasal Glucagon: Resolution of Hypoglycemia. International Journal of Molecular Sciences, 2019, 20, 3646.	1.8	15
450	Association between diabetes and mood disorders and the potential use of anti-hyperglycemic agents as antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 95, 109720.	2.5	35
451	Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 70, 793-810.	1.2	38
452	Effects of obesity induced by high-calorie diet and its treatment with exenatide on muscarinic acetylcholine receptors in rat hippocampus. Biochemical Pharmacology, 2019, 169, 113630.	2.0	6
453	Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity. ACS Pharmacology and Translational Science, 2019, 2, 468-484.	2.5	21
454	Evaluation of the effects of liraglutide on the development of epilepsy and behavioural alterations in two animal models of epileptogenesis. Brain Research Bulletin, 2019, 153, 133-142.	1.4	24
455	Stereo- and Enantioselective Addition of Organolithiums to 2-Oxazolinylazetidines as a Synthetic Route to 2-Acylazetidines. Frontiers in Chemistry, 2019, 7, 614.	1.8	7
456	Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 2019, 30, 72-130.	3.0	850
457	Neuregulin1Î² improves both spatial and associative learning and memory in Alzheimer model of rats possibly through signaling pathways other than Erk1/2. Neuropeptides, 2019, 78, 101963.	0.9	18
458	Evidence of Repurposing Drugs and Identifying Contraindications from Real World Study in Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 954-963.	1.7	4

#	Article	IF	Citations
459	Regulation of Memory Function by Feeding-Relevant Biological Systems: Following the Breadcrumbs to the Hippocampus. Frontiers in Molecular Neuroscience, 2019, 12, 101.	1.4	33
460	DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling. Neuropharmacology, 2019, 157, 107668.	2.0	43
461	The role of short-chain fatty acids in microbiotaâ€“gutâ€“brain communication. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 461-478.	8.2	1,519
462	Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency. Molecular Pharmaceutics, 2019, 16, 2278-2295.	2.3	54
463	Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimerâ€™s disease: study protocol for a randomised controlled trial (ELAD study). Trials, 2019, 20, 191.	0.7	127
464	Liraglutide and its Neuroprotective Propertiesâ€”Focus on Possible Biochemical Mechanisms in Alzheimerâ€™s Disease and Cerebral Ischemic Events. International Journal of Molecular Sciences, 2019, 20, 1050.	1.8	50
465	Neuroprotective effects of an engineered commensal bacterium in the 1â€methylâ€4â€phenylâ€1, 2, 3, 6â€tetrahydropyridine Parkinson disease mouse model via producing glucagonâ€like peptideâ€1. Journal of Neurochemistry, 2019, 150, 441-452.	2.1	48
466	Therapeutic Potential of Glucagon-Like Peptide-1 Cleavage Product for Alzheimerâ€™s Disease. Neuroscience Bulletin, 2019, 35, 934-936.	1.5	0
467	GLP-1â€™s role in neuroprotection: a systematic review. Brain Injury, 2019, 33, 734-819.	0.6	59
468	Semaglutide is Neuroprotective and Reduces Î±-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2019, 9, 157-171.	1.5	92
469	The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology, 2019, 10, 155.	1.5	395
470	Fructooligosaccharides Ameliorating Cognitive Deficits and Neurodegeneration in APP/PS1 Transgenic Mice through Modulating Gut Microbiota. Journal of Agricultural and Food Chemistry, 2019, 67, 3006-3017.	2.4	86
471	Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3Î². Biochemical and Biophysical Research Communications, 2019, 511, 154-160.	1.0	46
472	Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 2515-2529.	1.1	20
473	Regulation of Diabetes: a Therapeutic Strategy for Alzheimer's Disease?. Journal of Korean Medical Science, 2019, 34, e297.	1.1	8
474	Prevention of pentylenetetrazole-induced kindling and behavioral comorbidities in mice by levetiracetam combined with the GLP-1 agonist liraglutide: Involvement of brain antioxidant and BDNF upregulating properties. Biomedicine and Pharmacotherapy, 2019, 109, 429-439.	2.5	60
475	Exendin-4 improves behaviorial deficits via GLP-1/GLP-1R signaling following partial hepatectomy. Brain Research, 2019, 1706, 116-124.	1.1	8
476	The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders. European Neuropsychopharmacology, 2019, 29, 137-146.	0.3	19

#	Article	IF	Citations
477	Cracking the combination: Gut hormones for the treatment of obesity and diabetes. Journal of Neuroendocrinology, 2019, 31, e12664.	1.2	29
478	Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimerâ€™s models. Nature Medicine, 2019, 25, 165-175.	15.2	511
479	Liraglutide Ameliorates Hyperhomocysteinemia-Induced Alzheimer-Like Pathology and Memory Deficits in Rats via Multi-molecular Targeting. Neuroscience Bulletin, 2019, 35, 724-734.	1.5	26
480	Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimerâ€™s and Parkinsonâ€™s Diseases. CNS Drugs, 2019, 33, 209-223.	2.7	49
481	Short-term improvements in cognitive function following vertical sleeve gastrectomy and Roux-en Y gastric bypass: a direct comparison study. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 2248-2257.	1.3	13
482	Dâ€Ser2â€oxyntomodulin ameliorated AÎ²31â€35â€induced circadian rhythm disorder in mice. CNS Neuroscience and Therapeutics, 2020, 26, 343-354.	1.9	9
483	Contemporary Updates on the Physiology of Glucagon like Peptide-1 and Its Agonist to Treat Type 2 Diabetes Mellitus. International Journal of Peptide Research and Therapeutics, 2020, 26, 1211-1221.	0.9	5
484	Neuromodulatory effects of anti-diabetes medications: A mechanistic review. Pharmacological Research, 2020, 152, 104611.	3.1	39
485	Allosteric modulators targeting GPCRs. , 2020, , 195-241.		1
486	DietaryAdvancedGlycationEnd Productsâ€“InducedCognitive Impairment in Aged ICR Mice: Protective Role of Quercetin. Molecular Nutrition and Food Research, 2020, 64, e1901019.	1.5	33
487	Resveratrol Modulates the Gut-Brain Axis: Focus on Glucagon-Like Peptide-1, 5-HT, and Gut Microbiota. Frontiers in Aging Neuroscience, 2020, 12, 588044.	1.7	24
488	Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimerâ€™s and Parkinsonâ€™s disease therapeutics. Biochemical Pharmacology, 2020, 180, 114187.	2.0	57
489	Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity. Biomaterials, 2020, 257, 120250.	5.7	7
490	The Neurotrophic Function of Glucagon-Like Peptide-1 Promotes Human Neuroblastoma Differentiation via the PI3K-AKT Axis. Biology, 2020, 9, 348.	1.3	9
491	Shared signaling pathways in Alzheimerâ€™s and metabolic disease may point to new treatment approaches. FEBS Journal, 2021, 288, 3855-3873.	2.2	19
492	Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. Frontiers in Pharmacology, 2020, 11, 1270.	1.6	43
493	Adiponectin: The Potential Regulator and Therapeutic Target of Obesity and Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 6419.	1.8	31
494	Non-glucose risk factors in the pathogenesis of diabetic peripheral neuropathy. Endocrine, 2020, 70, 465-478.	1.1	6

#	Article	IF	Citations
495	Design and Application in Delivery System of Intranasal Antidepressants. Frontiers in Bioengineering and Biotechnology, 2020, 8, 626882.	2.0	58
496	GLP-1R activation alters performance in cognitive tasks in a sex-dependent manner. Neurological Sciences, 2020, 42, 2911-2919.	0.9	4
497	Gut Microbiome Signatures Are Biomarkers for Cognitive Impairment in Patients With Ischemic Stroke. Frontiers in Aging Neuroscience, 2020, 12, 511562.	1.7	52
498	The microbiota-gut-brain axis: Focus on the fundamental communication pathways. Progress in Molecular Biology and Translational Science, 2020, 176, 43-110.	0.9	35
499	Inhibition of interleukin-6 on matrix protein production by glomerular mesangial cells and the pathway involved. American Journal of Physiology - Renal Physiology, 2020, 318, F1478-F1488.	1.3	15
500	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurology, The, 2020, 19, 582-590.	4.9	123
501	Linagliptin, the dipeptidyl peptidaseâ€4 enzyme inhibitor, lessens CHOP and GRP78 biomarkers levels in cisplatinâ€induced neurobehavioral deficits: A possible restorative gateway. Journal of Biochemical and Molecular Toxicology, 2020, 34, e22541.	1.4	8
502	Glucagon-like peptide-1 receptor agonist Exendin-4 improves neurological outcomes by attenuating TBI- induced inflammatory responses and MAPK activation in rats. International Immunopharmacology, 2020, 86, 106715.	1.7	14
503	The treament of hyperglycemia in acute ischemic stroke with incretin-based drugs. Pharmacological Research, 2020, 160, 105018.	3.1	5
504	Reframing appetitive reinforcement learning and reward valuation as effects mediated by hippocampal-dependent behavioral inhibition. Nutrition Research, 2020, 79, 1-12.	1.3	7
505	Brain Endothelial Cells Regulate Glucagon-Like Peptide 1 Entry Into the Brain via a Receptor-Mediated Process. Frontiers in Physiology, 2020, 11, 555.	1.3	16
506	Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Expert Opinion on Investigational Drugs, 2020, 29, 333-348.	1.9	94
507	Liraglutide Suppresses Tau Hyperphosphorylation, Amyloid Beta Accumulation through Regulating Neuronal Insulin Signaling and BACE-1 Activity. International Journal of Molecular Sciences, 2020, 21, 1725.	1.8	29
508	The Glucagon-Like Peptide-1 Analogue Liraglutide Reduces Seizures Susceptibility, Cognition Dysfunction and Neuronal Apoptosis in a Mouse Model of Dravet Syndrome. Frontiers in Pharmacology, 2020, 11, 136.	1.6	14
509	GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats. Science Translational Medicine, 2020, 12, .	5.8	65
510	Suppression of BACE1 and amyloidogenic/RAGE axis by sitagliptin ameliorates PTZ kindling-induced cognitive deficits in rats. Chemico-Biological Interactions, 2020, 328, 109144.	1.7	7
511	Sitagliptin improves functional recovery via GLPâ€1Râ€induced antiâ€apoptosis and facilitation of axonal regeneration after spinal cord injury. Journal of Cellular and Molecular Medicine, 2020, 24, 8687-8702.	1.6	16
512	Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. International Journal of Obesity, 2020, 44, 1254-1263.	1.6	54

#	Article	IF	Citations
513	The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: Relevance for bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 99, 109872.	2.5	21
514	Plasma N-Acetylaspartate Is Related to Age, Obesity, and Glucose Metabolism: Effects of Antidiabetic Treatment and Bariatric Surgery. Frontiers in Endocrinology, 2020, 11, 216.	1.5	10
515	Neuroprotection from Excitotoxic Injury by Local Administration of Lipid Emulsion into the Brain of Rats. International Journal of Molecular Sciences, 2020, 21, 2706.	1.8	9
516	Diabetesâ€“Alzheimer's Disease Link: Targeting Mitochondrial Dysfunction and Redox Imbalance. Antioxidants and Redox Signaling, 2021, 34, 631-649.	2.5	24
517	GLP-1 receptor agonists in the treatment of type 2 diabetes â€“ state-of-the-art. Molecular Metabolism, 2021, 46, 101102.	3.0	518
518	Identification of N-Terminally Diversified GLP-1R Agonists Using Saturation Mutagenesis and Chemical Design. ACS Chemical Biology, 2021, 16, 58-66.	1.6	5
519	Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. Endocrine Reviews, 2021, 42, 101-132.	8.9	115
520	GLP-1 mimetics and cognition. Life Sciences, 2021, 264, 118645.	2.0	32
521	Activation of glucagonâ€like peptideâ€1 receptors and skilled reach foraging. Addiction Biology, 2021, 26, e12953.	1.4	3
522	Role of Exendin-4 in Brain Insulin Resistance, Mitochondrial Function, and Neurite Outgrowth in Neurons under Palmitic Acid-Induced Oxidative Stress. Antioxidants, 2021, 10, 78.	2.2	8
523	Endocrine dysfunction and cognitive impairment. Minerva Endocrinology, 0, , .	0.6	3
524	Impact of Microbial Metabolites on Microbiotaâ€“Gutâ€“Brain Axis in Inflammatory Bowel Disease. International Journal of Molecular Sciences, 2021, 22, 1623.	1.8	56
525	Going with the grain: Fiber, cognition, and the microbiota-gut-brain-axis. Experimental Biology and Medicine, 2021, 246, 796-811.	1.1	47
526	Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity. Biomolecules, 2021, 11, 286.	1.8	20
527	Engineering of smart nanoconstructs for delivery of glucagon-like peptide-1 analogs. International Journal of Pharmaceutics, 2021, 597, 120317.	2.6	7
528	<scp>MRI</scp> measures of hypothalamic injury are associated with glucagonâ€like peptideâ€1 receptor agonist treatment response in people with hypothalamic obesity. Diabetes, Obesity and Metabolism, 2021, 23, 1532-1541.	2.2	12
529	GLP-1 Receptor Agonist Inhibited the Activation of RIPK1 for Alleviation the Neuronal Death and Neuroinflammation in APP/PS1 Mice. International Journal of Peptide Research and Therapeutics, 2021, 27, 1699-1707.	0.9	1
530	A Potential Mechanism Underlying the Therapeutic Effects of Progesterone and Allopregnanolone on Ketamine-Induced Cognitive Deficits. Frontiers in Pharmacology, 2021, 12, 612083.	1.6	10

#	Article	IF	Citations
531	Exendin-4 improves long-term potentiation and neuronal dendritic growth in vivo and in vitro obesity condition. Scientific Reports, 2021, 11, 8326.	1.6	7
532	A High-Fat Diet Increases Activation of the Glucagon-Like Peptide-1-Producing Neurons in the Nucleus Tractus Solitarii: an Effect that is Partially Reversed by Drugs Normalizing Glycemia. Cellular and Molecular Neurobiology, 2022, 42, 1995-2002.	1.7	2
533	The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases. International Journal of Neuroscience, 2023, 133, 473-491.	0.8	12
534	Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke. Basic Research in Cardiology, 2021, 116, 32.	2.5	32
535	Protective properties of GLPâ€1 and associated peptide hormones in neurodegenerative disorders. British Journal of Pharmacology, 2022, 179, 695-714.	2.7	55
536	Effect of Exenatide Use on Cognitive and Affective Functioning in Obese Patients With Type 2 Diabetes Mellitus. Journal of Clinical Psychopharmacology, 2021, Publish Ahead of Print, 428-435.	0.7	4
537	Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions. Neurological Sciences, 2021, 42, 3145-3166.	0.9	20
538	Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression. Pharmacological Reports, 2021, 73, 1020-1032.	1.5	23
539	The GLPâ€1/GIP dualâ€receptor agonist DA5â€CH inhibits the NFâ€ºB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLPâ€1 singleâ€receptor agonist NLY01. Brain and Behavior, 2021, 11, e2231.	1.0	26
540	Butyrate and the Intestinal Epithelium: Modulation of Proliferation and Inflammation in Homeostasis and Disease. Cells, 2021, 10, 1775.	1.8	152
541	Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing Î±-Synuclein and Oxidative Stress. Frontiers in Molecular Neuroscience, 2021, 14, 697440.	1.4	22
542	GLP-1R activation ameliorated novel-object recognition memory dysfunction via regulating hippocampal AMPK/NF-ÎºB pathway in neuropathic pain mice. Neurobiology of Learning and Memory, 2021, 182, 107463.	1.0	22
543	The Gutâ€“Brain Axis and Peroxisome Proliferator-Activated Receptors in the Regulation of Epileptogenesis. Journal of Evolutionary Biochemistry and Physiology, 2021, 57, 743-760.	0.2	2
544	Activation of Glucagonâ€like Peptideâ€1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolismâ€independent Pathway. Journal of the American Heart Association, 2021, 10, e020734.	1.6	24
545	Glucagon-like peptide-1 attenuated carboxymethyl lysine induced neuronal apoptosis via peroxisome proliferation activated receptor-Î³. Aging, 2021, 13, 19013-19027.	1.4	6
546	Diet-induced dysbiosis of the maternal gut microbiome in early life programming of neurodevelopmental disorders. Neuroscience Research, 2021, 168, 3-19.	1.0	15
547	GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Frontiers in Endocrinology, 2021, 12, 721135.	1.5	103
548	Brain GLPâ€1 and the regulation of food intake: GLPâ€1 action in the brain and its implications for GLPâ€1 receptor agonists in obesity treatment. British Journal of Pharmacology, 2022, 179, 557-570.	2.7	46

#	Article	IF	Citations
549	The therapeutic potential of GLP-1 analogues for stress-related eating and role of GLP-1 in stress, emotion and mood: a review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110303.	2.5	17
550	Targeting Metabolic Dysfunction for the Treatment of Mood Disorders: Review of the Evidence. Life, 2021, 11, 819.	1.1	10
551	Adaptation of AMPK-mTOR-signal pathways and lipid metabolism in response to low- and high-level rapeseed meal diet in Chinese perch (Siniperca chuatsi). Journal of Comparative Physiology B: Biochemical, Systemic, and Environmental Physiology, 2021, 191, 881-894.	0.7	5
552	Central GLP-1 contributes to improved cognitive function and brain glucose uptake after duodenum-jejunum bypass on obese and diabetic rats. American Journal of Physiology - Endocrinology and Metabolism, 2021, 321, E392-E409.	1.8	12
553	Memory regulation in feeding habit transformation to dead prey fish of Chinese perch (Siniperca) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5	0.9	3
554	GLP-1 and Underlying Beneficial Actions in Alzheimerâ€™s Disease, Hypertension, and NASH. Frontiers in Endocrinology, 2021, 12, 721198.	1.5	15
555	Exendin-4 Pretreatment Attenuates Kainic Acid-Induced Hippocampal Neuronal Death. Cells, 2021, 10, 2527.	1.8	5
556	Long-term functional alterations following prenatal GLP-1R activation. Neurotoxicology and Teratology, 2021, 87, 106984.	1.2	10
557	Multiple roles of short-chain fatty acids in Alzheimer disease. Nutrition, 2022, 93, 111499.	1.1	38
558	Diabetes mellitus and Parkinsonâ€™s disease: dangerous liaisons between insulin and dopamine. Neural Regeneration Research, 2022, 17, 523.	1.6	21
559	Couch Potato: The Antithesis of Hormesis. , 2010, , 139-151.		1
560	AÎ² Infusion and Related Models of Alzheimer Dementia. Neuromethods, 2011, , 347-370.	0.2	7
561	Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases. International Review of Neurobiology, 2020, 155, 65-89.	0.9	9
562	Repurposing GLP1 agonists for neurodegenerative diseases. International Review of Neurobiology, 2020, 155, 91-112.	0.9	7
563	Type 2 diabetes and cognitive dysfunctionâ€”towards effective management of both comorbidities. Lancet Diabetes and Endocrinology,the, 2020, 8, 535-545.	5.5	192
565	Dysregulation of insulin receptor substrate 2 in Î² cells and brain causes obesity and diabetes. Journal of Clinical Investigation, 2004, 114, 908-916.	3.9	262
566	An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimerâ€™s diseaseâ€“associated AÎ² oligomers. Journal of Clinical Investigation, 2012, 122, 1339-1353.	3.9	697
567	Exenatide and the treatment of patients with Parkinsonâ€™s disease. Journal of Clinical Investigation, 2013, 123, 2730-2736.	3.9	361

#	Article	IF	Citations
568	Genetic Deficiency in Neprilysin or Its Pharmacological Inhibition Initiate Excessive Stress-Induced Alcohol Consumption in Mice. PLoS ONE, 2012, 7, e50187.	1.1	4
569	Chronic Treatment with the GLP1 Analogue Liraglutide Increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model. PLoS ONE, 2013, 8, e58784.	1.1	103
570	Transcriptional Evidence for the Role of Chronic Venlafaxine Treatment in Neurotrophic Signaling and Neuroplasticity Including also Glutatmatergic- and Insulin-Mediated Neuronal Processes. PLoS ONE, 2014, 9, e113662.	1.1	52
571	Exenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in Rats. PLoS ONE, 2015, 10, e0141921.	1.1	23
572	Exendin-4 effects on islet volume and number in mouse pancreas. Brazilian Journal of Pharmaceutical Sciences, 2013, 49, 745-752.	1.2	2
573	Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease. EXCLI Journal, 2015, 14, 684-96.	0.5	20
574	Evolving Insights into the Pathophysiology of Diabetic Neuropathy: Implications of Malfunctioning Glia and Discovery of Novel Therapeutic Targets. Current Pharmaceutical Design, 2016, 22, 738-757.	0.9	23
575	A Pilot Study of Exenatide Actions in Alzheimerâ€™s Disease. Current Alzheimer Research, 2019, 16, 741-752.	0.7	75
576	Dual Inhibition of DPP-4 and Cholinesterase Enzymes by the Phytoconstituents of the Ethanolic Extract of Prosopis cineraria Pods: Therapeutic Implications for the Treatment of Diabetes-associated Neurological Impairments. Current Alzheimer Research, 2020, 16, 1230-1244.	0.7	7
577	Towards a â€œMetabolicâ€•Subtype of Major Depressive Disorder: Shared Pathophysiological Mechanisms May Contribute to Cognitive Dysfunction. CNS and Neurological Disorders - Drug Targets, 2015, 13, 1693-1707.	0.8	46
578	Clinical translation of stem cell therapy in traumatic brain injury: the potential of encapsulated mesenchymal cell biodelivery of glucagon-like peptide-1. Dialogues in Clinical Neuroscience, 2011, 13, 279-286.	1.8	40
579	Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury. Frontiers in Cell and Developmental Biology, 2019, 7, 356.	1.8	29
580	Glucagon like peptide-1: A new therapeutic target for diabetes mellitus. Indian Journal of Pharmacology, 2006, 38, 231.	0.4	3
581	Tackling dipeptidyl peptidase IV in neurological disorders. Neural Regeneration Research, 2018, 13, 26.	1.6	19
582	Central Functions of Glucagon-like Peptide-1: Roles in Energy Regulation and Neuroprotection. Journal of Steroids & Hormonal Science, 2015, 06, .	0.1	3
583	Alzheimerâ€™s and Hyperglycemia: Role of the Insulin Signaling Pathway and GSK-3 Inhibition in Paving a Path to Dementia. Cureus, 2020, 12, e6885.	0.2	10
584	Endocrine dysfunction and cognitive impairment. Minerva Endocrinology, 2021, 46, 335-349.	0.6	8
585	Potential new therapeutic target for Alzheimer's disease: Glucagonâ€like peptideâ€1. European Journal of Neuroscience, 2021, 54, 7749-7769.	1.2	7

#	Article	IF	Citations
586	Predictive Value of Gut Microbiome for Cognitive Impairment in Patients with Hypertension. Disease Markers, 2021, 2021, 1-9.	0.6	3
587	Brain energy failure in dementia syndromes: Opportunities and challenges for glucagonâ€like peptideâ€1 receptor agonists. Alzheimer's and Dementia, 2022, 18, 478-497.	0.4	13
588	Lamiophlomis herba: A comprehensive overview of its chemical constituents, pharmacology, clinical applications, and quality control. Biomedicine and Pharmacotherapy, 2021, 144, 112299.	2.5	8
589	Metabolic Actions of Glucagon-Like Peptides. Oxidative Stress and Disease, 2005, , .	0.3	0
590	Glucagon-like peptide 1 receptor. The AFCS-nature Molecule Pages, 0, , .	0.2	1
591	Glucagon-like Peptides and Insulin Sensitivity. , 2008, , 233-254.		0
592	Novye vozmozhnosti v terapii SD 2 tipa: liraglutid - analog chelovecheskogo glyukagonopodobnogo peptida-1. Diabetes Mellitus, 2008, 11, 67-70.	0.5	0
593	The role of glucagonâ€‘like peptide 1 in glucose homeostasis and in other aspects of human physiology. Polish Archives of Internal Medicine, 2009, 119, 743-751.	0.3	3
595	DPP 4 (dipeptidylpeptidase-4) inhibitors: beyond glycemic control. IOSR Journal of Pharmacy, 2013, 3, 81-85.	0.1	0
597	Glucagon peptide-like 1 receptor (GLP-1R) expression per se: a new insight into neurodegenerative disease?. Neural Regeneration Research, 2015, 10, 1055.	1.6	3
598	Application prospects of glucagon-like peptide-1 receptor agonists in treatment of metabolic diseases. World Chinese Journal of Digestology, 2020, 28, 393-400.	0.0	0
599	Coming of Age for the Incretins. , 2008, , 269-290.		0
600	Neuroprotective effects of exendin-4 in rat model of spinal cord injury via inhibiting mitochondrial apoptotic pathway. International Journal of Clinical and Experimental Pathology, 2015, 8, 4837-43.	0.5	17
601	Brain Uptake of Neurotherapeutics after Intranasal versus Intraperitoneal Delivery in Mice. Journal of Neurology and Neurosurgery, 2015, 2, .	0.3	25
602	Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3Î². American Journal of Translational Research (discontinued), 2017, 9, 247-260.	0.0	21
603	Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Med, 2021, 2, 1203-1230.	2.2	17
604	Iterative Metaplasticity Across Timescales: How Circadian, Ultradian, and Infradian Rhythms Modulate Memory Mechanisms. Journal of Biological Rhythms, 2022, 37, 29-42.	1.4	2
605	Diabetic Peripheral Neuropathy Associated with Cardiovascular Risk Factors and Glucagon-Like Peptide-1 Concentrations Among Newly Diagnosed Patients with Type 2 Diabetes Mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2022, Volume 15, 35-44.	1.1	12

#	Article	IF	Citations
606	Arterial responses to infusion of Glucagon-like Peptide-1 in humans: A randomized trial study. Peptides, 2022, 150, 170736.	1.2	0
607	Astrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives. Frontiers in Physiology, 2021, 12, 825816.	1.3	76
608	Short chain fatty acids: Microbial metabolites for gut-brain axis signalling. Molecular and Cellular Endocrinology, 2022, 546, 111572.	1.6	117
609	Effects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus. Vitamins and Hormones, 2022, 118, 457-478.	0.7	7
610	Brain uptake and distribution patterns of 2-hydroxypropyl-ÃŸ-cyclodextrin after intrathecal and intranasal administration. Journal of Pharmacy and Pharmacology, 2022, 74, 1152-1159.	1.2	1
611	Intake of flavonoids from Astragalus membranaceus ameliorated brain impairment in diabetic mice via modulating brain-gut axis. Chinese Medicine, 2022, 17, 22.	1.6	20
612	Cardiovascular effects of GLP-1 receptor agonism. Advances in Pharmacology, 2022, , 213-254.	1.2	5
613	Treatment with glucagonâ€like peptideâ€1 receptor agonists and incidence of dementia: Data from pooled doubleâ€blind randomized controlled trials and nationwide disease and prescription registers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12268.	1.8	39
614	Targeting Microglia to Treat Degenerative Eye Diseases. Frontiers in Immunology, 2022, 13, 843558.	2.2	24
615	Gastrointestinal Incretinsâ€"Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Diseaseâ€"State of the Art. Biology, 2022, 11, 288.	1.3	9
616	The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism. Frontiers in Endocrinology, 2022, 13, 863184.	1.5	5
617	Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes. Frontiers in Endocrinology, 2022, 13, 838410.	1.5	42
618	The GLP-1 receptor agonist Exendin-4 modulates hippocampal NMDA-receptor signalling in aged rats and improves cognitive impairment in diabetic elderly patients. Journal of Gerontology and Geriatrics, 0, , 1-7.	0.2	1
619	Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research. Frontiers in Neurology, 2022, 13, 844697.	1.1	12
621	Type 2 Diabetes Mellitus as a Risk Factor for Alzheimerâ€™s Disease: Review and Meta-Analysis. Biomedicines, 2022, 10, 778.	1.4	21
622	Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome. Inflammopharmacology, 2022, 30, 919-934.	1.9	29
623	Type 2 diabetes mellitus-associated cognitive dysfunction: Advances in potential mechanisms and therapies. Neuroscience and Biobehavioral Reviews, 2022, 137, 104642.	2.9	27
624	New Horizonsâ€"Cognitive Dysfunction Associated With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 929-942.	1.8	5

#	Article	IF	Citations
625	A peripheral lipid sensor GPR120 remotely contributes to suppression of PGD2-microglia-provoked neuroinflammation and neurodegeneration in the mouse hippocampus. Journal of Neuroinflammation, 2021, 18, 304.	3.1	10
626	Liraglutide Reduces Vascular Damage, Neuronal Loss, and Cognitive Impairment in a Mixed Murine Model of Alzheimerâ€™s Disease and Type 2 Diabetes. Frontiers in Aging Neuroscience, 2021, 13, 741923.	1.7	17
627	Linagliptin, a Selective Dipeptidyl Peptidase-4 Inhibitor, Reduces Physical and Behavioral Effects of Morphine Withdrawal. Molecules, 2022, 27, 2478.	1.7	8
648	The novel adamantane derivatives as potential mediators of inflammation and neural plasticity in diabetes mice with cognitive impairment. Scientific Reports, 2022, 12, 6708.	1.6	11
649	Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2022, 65, 7088-7105.	2.9	21
650	Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbidities. Neuropeptides, 2022, 94, 102250.	0.9	15
651	Insight into the role of DPP-4 in fibrotic wound healing. Biomedicine and Pharmacotherapy, 2022, 151, 113143.	2.5	11
652	Neuroinflammation in Parkinsonâ€™s Disease â€“ Putative Pathomechanisms and Targets for Disease-Modification. Frontiers in Immunology, 2022, 13, .	2.2	42
653	GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight. Cells, 2022, 11, 2023.	1.8	11
654	Exercise Improves Spatial Learning and Memory Performance through the Central GLP-1 Receptors. Behavioural Neurology, 2022, 2022, 1-6.	1.1	0
655	Liraglutide chronic treatment prevents development of tolerance to antiseizure effects of diazepam in genetically epilepsy prone rats. European Journal of Pharmacology, 2022, 928, 175098.	1.7	3
656	Differential association between the GLP1R gene variants and brain functional connectivity according to the severity of alcohol use. Scientific Reports, 2022, 12, .	1.6	6
657	Neuroinflammation in Parkinson"s Disease and its Treatment Opportunities. Balkan Medical Journal, 2022, 39, 318-333.	0.3	11
658	Genetic disruption of the Gipr in Apoeâ^'/â^' mice promotes atherosclerosis. Molecular Metabolism, 2022, 65, 101586.	3.0	4
659	Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. , 2022, 239, 108277.		15
660	Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities. , 2022, 239, 108270.		9
661	Effect of glucagon-like peptide-1 on differentiation of adipose derived mesenchymal stem cells into cardiomyocytes. Ege TÄ±p Dergisi, 2022, 61, 507-517.	0.1	0
662	Potential role of IGF-1/GLP-1 signaling activation in intracerebral hemorrhage. Current Research in Neurobiology, 2022, 3, 100055.	1.1	1

#	Article	IF	Citations
663	The Anti-Seizure Effect of Liraglutide on Ptz-Induced Convulsions Through its Anti-Oxidant and Anti-Inflammatory Properties. Neurochemical Research, 2023, 48, 188-195.	1.6	5
664	Diabetic cardiomyopathy: the need for adjusting experimental models to meet clinical reality. Cardiovascular Research, 2023, 119, 1130-1145.	1.8	6
665	The neuroprotective effects of glucagon-like peptide 1 in Alzheimerâ€™s and Parkinsonâ€™s disease: An in-depth review. Frontiers in Neuroscience, 0, 16, .	1.4	39
666	Glucagonâ€like peptideâ€1 receptor differentially controls mossy cell activity across the dentate gyrus longitudinal axis. Hippocampus, 2022, 32, 797-807.	0.9	3
667	Effect of Vildagliptin on Cognitive Deficits in an Experimental Model of Alzheimerâ€™s Disease. Biomedical and Pharmacology Journal, 2022, 15, 1261-1270.	0.2	0
668	Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions. Neuroscience and Biobehavioral Reviews, 2022, 142, 104896.	2.9	25
669	Specific interaction of insulin receptor and GLP-1 receptor mediates crosstalk between their signaling. Biochemical and Biophysical Research Communications, 2022, 636, 31-39.	1.0	1
670	Involvement of Intestinal Enteroendocrine Cells in Neurological and Psychiatric Disorders. Biomedicines, 2022, 10, 2577.	1.4	6
671	Plant bioactives in balancing glucose homeostasis during aging and related diseases. , 2023, , 63-83.		0
672	The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimerâ€™s disease. Frontiers in Endocrinology, 0, 13, .	1.5	7
673	Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacological Research, 2022, 186, 106550.	3.1	30
674	Physical exercise promotes memory function in diabetes mellitus rats: a look at glucagon like peptide-1 and glucagon like peptide-1 receptor. Comparative Exercise Physiology, 2023, 19, 71-79.	0.3	0
675	Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China. Frontiers in Neurology, 0, 13, .	1.1	6
676	Roseburia intestinalis Modulates PYY Expression in a New a Multicellular Model including Enteroendocrine Cells. Microorganisms, 2022, 10, 2263.	1.6	2
677	Alteration of brain nuclei in obese children with and without Prader-Willi syndrome. Frontiers in Neuroinformatics, 0, 16, .	1.3	1
678	Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases. European Journal of Pharmacology, 2023, 938, 175439.	1.7	12
679	Efficacy and safety of hypoglycemic drugs in improving cognitive function in patients with Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis. Frontiers in Neurology, 0, 13, .	1.1	2
680	MED13 and glycolysis are conserved modifiers of Î±-synuclein-associated neurodegeneration. Cell Reports, 2022, 41, 111852.	2.9	8

#	Article	IF	Citations
681	Vildagliptin restores cognitive function and mitigates hippocampal neuronal apoptosis in cisplatin-induced chemo-brain: Imperative roles of AMPK/Akt/CREB/ BDNF signaling cascades. Biomedicine and Pharmacotherapy, 2023, 159, 114238.	2.5	3
682	Metabolic Diffusion in Neuropathologies: The Relevance of Brain-Liver Axis. Frontiers in Physiology, 0, 13, .	1.3	6
683	GLP-1 agonist Liraglutide prevents MKâ€‘801â€“induced schizophreniaâ€‘like behaviors and BDNF, CREB, p-CREB, Trk-B expressions in the hippocampus and prefrontal cortex in Balb/c mice. Behavioural Brain Research, 2023, 445, 114386.	1.2	5
684	Genetic modifiers of synucleinopathiesâ€”lessons from experimental models. , 2023, 2, .		0
685	Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nature Reviews Cardiology, 2023, 20, 463-474.	6.1	46
686	The expanding incretin universe: from basic biology to clinical translation. Diabetologia, 2023, 66, 1765-1779.	2.9	26
691	DPP-4 inhibitors and type 2 diabetes mellitus in Parkinsonâ€™s disease: a mutual relationship. Pharmacological Reports, 2023, 75, 923-936.	1.5	3
701	An Imbalance of Pathophysiologic Factors in Late Postprandial Hypoglycemia Post Bariatric Surgery: A Narrative Review. Obesity Surgery, 2023, 33, 2927-2937.	1.1	2
716	Exercise and the Brainâ€“Gut Axis. , 2024, , 241-259.		0